News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
TFF Pharmaceuticals Inc. And Uniphar Durbin Ireland Ltd. Announce the Launch of Expanded Access Program for Voriconazole Inhalation Powder
Monday, July 31, 2023Uniphar Durbin Ireland Limited Durbin or the Company and TFF Pharmaceuticals Inc Nasdaq TFFP have jointly announced the launch of an Expanded Access Program EAP for TFFVORI
Genenta's Ongoing Clinical Trial Progress and Ambitious Plans for Solid Tumor Treatments
Saturday, July 29, 2023Genenta Science NASDAQ GNTA has provided an update on its clinicalstage immunooncology IO efforts focusing on the development of Temferon a cellbased platform aimed at providing safe and durable treatments for solid tumors
FDA Grants Breakthrough Therapy Designation to NS-089/NCNP-02 for Duchenne Muscular Dystrophy Treatment
Saturday, July 29, 2023NS Pharma Inc announced today that the US Food Drug Administration FDA has granted Breakthrough Therapy Designation to NSNCNP an investigational candidate developed for patients with Duchenne muscular dystrophy amenable to exon skipping therapy
IO Biotech Commences Phase 1 Trial, Administers First Dose to Patient at University of California Davis Comprehensive Cancer Center
Saturday, July 29, 2023IO Biotech Nasdaq IOBT has recently announced the initiation of an investigatorinitiated trial in collaboration with the University of California Davis Comprehensive Cancer Center
Celularity and Verséa Ophthalmics Establish Exclusive Agreement to Commercialize Biovance® and Biovance® 3L Ocular for Ophthalmic Applications in the U.S.
Friday, July 28, 2023Celularity Inc Nasdaq CELU and Versa Ophthalmics LLC have entered into an exclusive US commercialization agreement according to their joint announcement Versa Ophthalmics a company based in Tampa FL specializes in delivering complete ocular pointofca...
Peptomyc Receives Approval for Phase 1b Trial Testing OMO-103 in Combination with Standard of Care for PDAC Patients
Friday, July 28, 2023Peptomyc SL is a specialized biotech company dedicated to developing protein therapeutics for cancer treatment The company has received full approval for its Phase b clinical trial which aims to evaluate the combination of OMO a groundbreaking MYC in...
Hikma Ventures Invests in Octave Bioscience, a Precision Care Platform Focused on Multiple Sclerosis and Other Neurodegenerative Diseases
Thursday, July 27, 2023Hikma Pharmaceuticals PLC Hikma a multinational pharmaceutical company has made a strategic investment through its venture capital arm Hikma Ventures in Octave Bioscience
Pharmabcine Commences Phase I Clinical Trial of Novel TIE2 Agonistic Antibody for NAMD, Administering Initial Patient Dose
Thursday, July 27, 2023PharmAbcine Inc KOSDAQ ks is a clinicalstage biotech company that focuses on developing nextgeneration antibody therapeutics
Myopax's Novel Regenerative Cell Therapy for Exstrophy-Epispadias Complex Granted FDA Orphan Drug Designation
Thursday, July 27, 2023MyoPax a biotechnology company has received Orphan Drug Designation from the US Food and Drug Administration FDA for its advanced regenerative cell therapy aimed at treating ExstrophyEpispadias Complex EEC
Recce Pharmaceuticals Initiates Phase I/II Rapid Infusion Clinical Trial of RECCE® 327 for UTI at Scientia Clinical Research
Thursday, July 27, 2023Reece Pharmaceuticals Ltd ASX RCE FSE RQ has made an exciting announcement regarding the progress of its Phase III clinical trial for a new class of synthetic antiinfectives targeting urinary tract infections UTIs
